

Carolina Herrera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8953196/publications.pdf>

Version: 2024-02-01

32
papers

540
citations

686830

13
h-index

676716

22
g-index

33
all docs

33
docs citations

33
times ranked

964
citing authors

#	ARTICLE	IF	CITATIONS
1	Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates. <i>Vaccines</i> , 2022, 10, 187.	2.1	2
2	HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory TÂcells. <i>Cell Reports</i> , 2022, 39, 110650.	2.9	6
3	The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans. <i>IScience</i> , 2022, , 104409.	1.9	4
4	Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue. <i>Pharmaceutics</i> , 2022, 14, 1285.	2.0	3
5	Early Colorectal Responses to HIV-1 and Modulation by Antiretroviral Drugs. <i>Vaccines</i> , 2021, 9, 231.	2.1	7
6	Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2129-2136.	1.3	10
7	The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate. <i>Aids</i> , 2021, 35, 1907-1917.	1.0	5
8	Peptide Amphiphilic-Based Supramolecular Structures with Anti-HIV-1 Activity. <i>Bioconjugate Chemistry</i> , 2021, 32, 1999-2013.	1.8	5
9	Optimized protocol for a quantitative SARS-CoV-2 duplex RT-qPCR assay with internal human sample sufficiency control. <i>Journal of Virological Methods</i> , 2021, 294, 114174.	1.0	16
10	Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial. <i>HIV Research and Clinical Practice</i> , 2021, , 1-9.	1.1	0
11	Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. <i>Lancet Microbe</i> , The, 2020, 1, e300-e307.	3.4	92
12	Importance of structure-based studies for the design of a novel HIV-1 inhibitor peptide. <i>Scientific Reports</i> , 2020, 10, 14430.	1.6	7
13	Efficacy of silk fibroin biomaterial vehicle for <i>in vivo</i> mucosal delivery of Griffithsin and protection against HIV and SHIV infection <i>ex vivo</i> . <i>Journal of the International AIDS Society</i> , 2020, 23, e25628.	1.2	14
14	The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: <i>in vitro</i> and <i>ex vivo</i> Models. <i>Frontiers in Pharmacology</i> , 2019, 10, 578.	1.6	4
15	CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype. <i>Mucosal Immunology</i> , 2019, 12, 1212-1219.	2.7	23
16	Sustained release silk fibroin discs: Antibody and protein delivery for HIV prevention. <i>Journal of Controlled Release</i> , 2019, 301, 1-12.	4.8	25
17	Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 348-355.	0.9	7
18	Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors <i>In Vitro</i> and <i>Ex Vivo</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	8

#	ARTICLE	IF	CITATIONS
19	Analytical Advances in the <i>Ex Vivo</i> Challenge Efficacy Assay. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 395-403.	0.5	14
20	Stabilization and Sustained Release of HIV Inhibitors by Encapsulation in Silk Fibroin Disks. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 1654-1665.	2.6	19
21	Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 334-338.	0.5	10
22	Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates. <i>Aids</i> , 2016, 30, 1015-1025.	1.0	17
23	Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 252-257.	0.9	25
24	HIV-1 CNS in vitro infectivity models based on clinical CSF samples. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 235-243.	1.3	6
25	Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection. <i>PLoS ONE</i> , 2016, 11, e0143109.	1.1	51
26	Colorectal Mucus Binds DC-SIGN and Inhibits HIV-1 Trans-Infection of CD4+ T-Lymphocytes. <i>PLoS ONE</i> , 2015, 10, e0122020.	1.1	11
27	Exploring Innovative Approaches to the Formulation of Microbicides to Boost Antiretroviral Drug Delivery and Activity at Mucosal Sites. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A150-A151.	0.5	0
28	Combinations of Entry and Reverse Transcriptase Inhibitors as Candidate Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A213-A213.	0.5	0
29	Candidate Microbicides and Their Mechanisms of Action. <i>Current Topics in Microbiology and Immunology</i> , 2013, 383, 1-25.	0.7	16
30	Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides. <i>Current HIV Research</i> , 2012, 10, 42-52.	0.2	20
31	Preclinical Evaluation of the HIV-1 Fusion Inhibitor L'644 as a Potential Candidate Microbicide. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2347-2356.	1.4	33
32	Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1797-1807.	1.4	77